A5029596720- Heart Failure Treatment and Management
- Diabetes Treatment and Management
- Pharmaceutical Practices and Patient Outcomes
- Cardiovascular Function and Risk Factors
- Acute Myocardial Infarction Research
- Cardiac Health and Mental Health
- Chronic Kidney Disease and Diabetes
- Pancreatic function and diabetes
NHS Greater Glasgow and Clyde
2019-2025
Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with reduced ejection fraction (HFrEF). However, their effects on cardiac structure function HFrEF are uncertain.We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF [Studies Empagliflozin Its Cardiovascular, Renal Metabolic Effects Patients With Diabetes Mellitus, or Prediabetes, Heart Failure]) to investigate empagliflozin...
<title>Abstract</title> Background Chronic kidney disease (CKD) is a leading cause of premature mortality, often coexisting with cardiovascular and diabetes mellitus; disproportionately affecting socioeconomically deprived groups. CKD projected to increase due ageing, obesity diabetes. General practice clinical pharmacists (GPCPs) have been shown be effective in challenging chronic prescribing. GPCP services for remains underexplored. Aim To scope the potential GPCP-led multidisciplinary...
Glasgow city has the highest cardiovascular disease (CVD) mortality rate in UK. Patients with left ventricular systolic dysfunction after acute myocardial infarction represent a ‘high-risk’ cohort for adverse CVD outcomes. The optimisation of secondary prevention medication this group is often suboptimal. Our aim was to improve use and target dosing ACE inhibitors (ACEI), angiotensin II receptor blockers (ARBs) beta-blockers such patients, through pharmacist-led clinics cardiology...
Abstract Objectives Left ventricular systolic dysfunction (LVSD) is common following myocardial infarction (MI). Pharmacological management of secondary prevention known to be sub-optimal. Integration pharmacists into clinical teams improves prescribing and quantitative outcomes. Few data have been published on patient views pharmacist input. We aimed explore experiences attending a dedicated independent prescriber (PIP)-led clinic. Methods Semi-structured face-to-face interviews....